- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Child life specialist.
Displaying page 1 of 1.
EudraCT Number: 2004-003803-19 | Sponsor Protocol Number: WXL101497 | Start Date*: 2004-11-10 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch... | ||
Medical condition: Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000434-34 | Sponsor Protocol Number: UMCU-VASC-CO-003 | Start Date*: 2023-04-12 |
Sponsor Name:University Medical Centre Utrecht | ||
Full Title: A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization. | ||
Medical condition: Pseudoxanthoma elasticum | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022114-12 | Sponsor Protocol Number: MW012 | Start Date*: 2010-12-20 |
Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG | ||
Full Title: Multizentrische prospektive randomisierte kontrollierte offene Phase IV Studie zur Evaluation von Synergien zwischen WS® 1070 und strukturiertem Stressmanagement bei Patienten mit nachlassender Lei... | ||
Medical condition: Asthenia and decreased concentration capacity as well as fatigue and feeling of weakness along with subjective stress | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004088-31 | Sponsor Protocol Number: B4Z-XM-LYDM | Start Date*: 2005-04-19 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002817-21 | Sponsor Protocol Number: AC-065A310 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) ES (Ongoing) HU (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016457-18 | Sponsor Protocol Number: E05-CL-3001 | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd | |||||||||||||
Full Title: A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain | |||||||||||||
Medical condition: Peripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Perip... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FR (Completed) BE (Completed) GB (Completed) CZ (Completed) FI (Completed) ES (Completed) AT (Completed) IT (Completed) HU (Completed) NL (Completed) SK (Completed) PL (Completed) SI (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007698-22 | Sponsor Protocol Number: R2-CHOP | Start Date*: 2008-07-10 |
Sponsor Name:GELARC | ||
Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA | ||
Medical condition: B cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2023-000785-33 | Sponsor Protocol Number: HST20-CL01 | Start Date*: 2023-08-18 |
Sponsor Name:HemoShear Therapeutics | ||
Full Title: A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-Period Crossover S... | ||
Medical condition: Methylmalonic Acidemia (MMA) Propionic Acidemia (PA) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-004085-17 | Sponsor Protocol Number: 19IC5548 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial) | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004757-28 | Sponsor Protocol Number: RR07/8350 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised controlled single-blind trial to compare intensive management vs standard care in early psoriatic arthritis | |||||||||||||
Medical condition: Newly diagnosed psoriatic arthritis of less than two years symptom duration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003372-37 | Sponsor Protocol Number: ET11-072 | Start Date*: 2014-06-04 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre... | |||||||||||||
Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022413-26 | Sponsor Protocol Number: IDEAL-Study | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study) | |||||||||||||
Medical condition: Patients in late stage of HIV-infection, treatment naive or without ART for the last 6 month with an acute AIDS-defining illness, namely PCP or TE. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002241-37 | Sponsor Protocol Number: 2006/VCC/0039 (WCTU01) | Start Date*: 2007-04-17 | |||||||||||
Sponsor Name:Velindre NHS Trust | |||||||||||||
Full Title: A randomised phase II/III multi-centre clinical trial of definitive chemo-radiaiton, with or without cetuximab, in carcinoma of the oesophagus | |||||||||||||
Medical condition: in-operable carcinoma of the oesophagus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004980-39 | Sponsor Protocol Number: Amiloride02 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis | |||||||||||||
Medical condition: Optic Neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001906-24 | Sponsor Protocol Number: LAMA/2021/1 | Start Date*: 2022-11-14 | ||||||||||||||||
Sponsor Name:Medical University in Lodz | ||||||||||||||||||
Full Title: LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial . | ||||||||||||||||||
Medical condition: Patients with ADHD and type I diabetes. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004888-54 | Sponsor Protocol Number: E2020-G000-326 | Start Date*: 2007-12-07 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) LT (Completed) ES (Completed) AT (Completed) DK (Completed) SE (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003551-11 | Sponsor Protocol Number: TILD-19-12 | Start Date*: 2020-08-17 |
Sponsor Name:Sun Pharma Advanced Research Company Ltd. | ||
Full Title: A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years... | ||
Medical condition: moderate to severe chronic plaque psoriasis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001263-20 | Sponsor Protocol Number: D-FR-01087-001 | Start Date*: 2018-12-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Ipsen Pharma SAS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An International Multicentre, Open-Label First in Human Phase I/II study to evaluate the safety, tolerability, biodistribution and antitumour activity of 177Lu-3BP-227 for the treatment of subjects... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with unresecable, metastatic or locally advanced cancers expressing Neurotensin Receptor 1 (NTSR1). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005067-32 | Sponsor Protocol Number: I4T-MC-JVCZ | Start Date*: 2015-11-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gast... | |||||||||||||
Medical condition: Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GR (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000128-16 | Sponsor Protocol Number: 2011-003 | Start Date*: 2012-07-30 | |||||||||||
Sponsor Name:Onyx Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
